Verve Therapeutics has started dosing patients in a phase 1b trial of its in vivo gene-editing drug for high cholesterol, designed to permanently switch off the PCSK9 gene with a one-shot treatment.
Trial will begin on September 21 and is expected to last 45 days at the High Court.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results